Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Prediction of tumor radiosensitivity by hexafluoromisonidazole retention monitored by sup 1 H/ sup 19 F magnetic resonance spectroscopy

Journal Article · · Cancer Communications; (United States)
OSTI ID:5555630
; ;  [1]
  1. Department of Radiology, Medical College of Wisconsin, Milwaukee (USA)

Hexafluoromisonidazole (CCI-103F) is a hypoxic cell label that can be measured by in vivo {sup 1}H/{sup 19}F magnetic resonance spectroscopy (MRS). The retention of CCI-103F in SCCVII tumors was found to be correlated with tumor size, with larger tumors retaining more label. Such a correlation was anticipated, as larger SCCVII tumors have larger hypoxic fractions. A significant but less strong correlation was also found between CCI-103F retention and the fraction of tumor cells surviving after 10 Gy irradiation, with tumors that retained larger amounts of CCI-103F having higher surviving fractions. These results indicated that non-invasive MRS measurement of CCI-103F retention could predict radiosensitivity in SCCVII tumors. The lack of a strong correlation between CCI-103F retention and radiosensitivity, however, indicated that hypoxic fraction was not the only factor influencing radiosensitivity in these tumors.

OSTI ID:
5555630
Journal Information:
Cancer Communications; (United States), Journal Name: Cancer Communications; (United States) Vol. 3:5; ISSN CNCME; ISSN 0955-3541
Country of Publication:
United States
Language:
English